亲缘单倍型和同胞相合造血干细胞移植治疗完全缓解期急性T淋巴细胞白血病疗效比较

OBJECTIVE: To compare the efficacy of haplotype hematopoietic stem celltransplantation（HIDT）and sibling matched hematopoietic stem cell transplantation（MSDT）in the treatment of complete remission（CR）acute T-lymphoblastic leukemia（T-ALL）. METHODS: We retrospectively analyzed the clinical characteristics and outcomes of 98 patients who underwent HSCT in Hebei Yanda Ludaopei hospital with HID（n＝81）or ISD（n＝17）between May 2012 and May 2016. RESULTS: The incidence of grades 2–4 and 3–4 acute-versus-host disease 100 days after HSCT were 51.9％（95％ Confidence interval [CI] 42.0％–64.0％）vs 29.4％（95％ CI 14.1％–61.4％）（P＝0.072）and 9.8％（95％ CI 5.1％–19.1％）vs 11.8％（95％ CI 3.2％–43.3％）（P＝1.000）for HIDT and MSDT. The 100-day cumulative incidences of CMV and EBV viremia were 53.1％（95％ CI 43.3％–65.2％）vs 29.4％（95％ CI 14.1％–61.4％）（P＝0.115）and 35.8％（95％ CI 26.8％–47.9％）vs11.8％（95％ CI 3.2％–43.3％）（P＝0.048）. The 5-year overall survival, leukemia-free survival, cumulative incidences of relapse, and no-relapse mortality were 60.5％（95％ CI 5.4％–49.0％）vs 68.8％（95％ CI 11.8％–40.0％）（P＝0.315）, 58.0％（95％ CI 5.5％–46.5％）vs 68.8％（95％ CI 11.8％–40.0％）（P＝0.258）, 16.1％（95％ CI 9.8％–26.4％）vs 11.8％（95％ CI 3.2％–43.3％）（P＝0.643）, 25.9％（95％ CI 17.9％–37.5％）vs 19.4％（95％ CI 6.9％–54.4％）（P＝0.386）for HIDT and MSDT, respectively. CONCLUSION: HID could be a valid alternative donor for patients with T-ALL in CR lacking an identical donor.